在HFpEF和心脏代谢疾病中的血清粉样蛋白A
Luo Liu1,2, Rongling Wang1,2,3, Stefano Strocchi1,2
1Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC), Charité-Universitätsmedizin Berlin, Berlin, Germany.
Basic research in cardiology
|November 28, 2025
概括
血清粉样蛋白A (SAA) 可能驱动心力衰竭的炎症,并保持喷射分数 (HFpEF) 和相关的代谢状况. 了解SAA的理解
科学领域:
- 心脏病学和代谢疾病研究研究
- 炎症和免疫学 炎症和免疫学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一种普遍的疾病,心脏代谢性HFpEF是由代谢功能障碍驱动的主要亚型.
- 系统性炎症和代谢障碍是HFpEF病原发生的关键因素,但在IL-6和TNF-α之外的上游炎症驱动因素尚未完全理解.
- 血清粉样蛋白A (SAA) 蛋白因其在慢性代谢疾病中的高水平而成为重要的参与者.
研究的目的:
- 审查SAA水平升高与诸如肥胖,糖尿病,MASLD和高血压等心脏代谢疾病之间的临床关联.
- 讨论SAA在心脏代谢HFpEF中的潜在致病机制,包括其在全身炎症,内皮功能障碍和心肌纤维化中的作用.
- 突出SAA作为心脏代谢HFpEF和相关疾病的潜在治疗标.
主要方法:
- 文献综述总结了SAA与心脏代谢疾病的临床关联.
- 讨论关于SAA在炎症和代谢功能障碍中的作用的临床前发现.
- 强调将SAA与HFpEF联系起来的病原遗传机制.
主要成果:
- 高SAA水平在临床上与肥胖,糖尿病,MASLD和高血压有关.
- 临床前研究表明,SAA有助于全身炎症,内皮功能障碍和心肌纤维化.
- SAA被认为是心脏代谢HFpEF的潜在驱动因素.
结论:
- SAA是包括HFpEF在内的心脏代谢疾病的发病的一个重要新兴因素.
- 对SAA作用的进一步研究可以促进HFpEF和相关代谢条件的诊断和治疗.
- 针对SAA可能为心脏代谢性HFpEF提供新的治疗策略.
更多相关视频
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
521
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
521
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Heart Failure II: Pathophysiology
685
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
01:23Rheumatic Heart Disease I: Introduction
408
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
408
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
01:27Heart Failure I: Introduction
670
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
670